Navigation Links
Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema

ase III trial. "I'd also like to thank all the HAE patients whose active participation in this study made this advance possible."

The Phase III study examined the efficacy and safety of C1-INH in patients suffering from moderate to severe acute HAE attacks in the face, abdomen or genitals. Laryngeal attacks, which can be life-threatening, were treated in the study with C1-INH on an open label basis. In the double-blind study, C1-INH was effective as analyzed across all attack sites. Additionally, 21 out of 21 laryngeal attacks were successfully treated with open-label C1-INH. To date, more than 400 acute treatments of C1-INH have been administered in all parts of the CHANGE trials with no drug-related serious adverse events (SAEs), no immunogenicity and no reports of injection site reactions.

"The results of this study confirm the extensive clinical experience in Europe where C1-inhibitor has been used to treat acute HAE attacks for more than 30 years. Upon FDA approval, this therapy will be welcomed by all patients with this debilitating disease," said Michael Frank, M.D., Distinguished Professor, Departments of Pediatrics and Medicine, Duke University School of Medicine, and an Investigator in the Phase III trial.

The CHANGE trial, the Company believes, is the world's largest double-blind, placebo-controlled study of C1-INH completed to date and is designed to determine the efficacy and safety of C1-INH in the treatment of HAE. In addition to the acute study, a second phase of the CHANGE trial is examining the prophylactic use of C1-INH in preventing HAE attacks in more severely affected patients. This prophylactic study is ongoing and is expected to conclude in the second half of 2007. Lev has also initiated two open label studies to provide HAE patients with continued access to C1-INH.

"This study brings us one step closer to making this important therapy available to patients in the U.S. who suffer from this debilitating condition, a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... -- Research and Markets has announced the addition ... Diarrhea, Mental Disorder) Market - Forecast to 2023" report ... report, the human microbiome market is segmented by application, disease, ... expected to be valued as $294 million in 2019 and ... the forecast period of 2019-2023. The market is driven by ...
(Date:9/19/2014)... -- Diplomat, the nation,s largest independent specialty pharmacy, has announced ... Board of Directors on September 15, 2014. Mr. Dreyer ... chair of the Audit Committee. Mr. ... and operating experience in the health care field.  Since ... officer, chief operating officer and secretary of Patient Safety ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2
... Professional Offers Patient Tips to Guard Against,Hospital Infections, ... Hospital,infections are among the top ten leading causes ... Centers for Disease Control. There,are countless stories about ... leave under much graver circumstances. As a,patient, knowing ...
... Findings Move Science Closer to Targeted, Improved Therapies , ... on Drug Abuse (NIDA), part of the National,Institutes of ... increase a person's ability to abstain from smoking. The,breakthrough ... Research Program and a team led by Dr. Jed ...
Cached Medicine Technology:Six Important Things to Know About Preventing Hospital Infections 2Six Important Things to Know About Preventing Hospital Infections 3NIDA Study Identifies Genes That Might Help Some People Abstain,from Smoking 2NIDA Study Identifies Genes That Might Help Some People Abstain,from Smoking 3
(Date:9/21/2014)... 21, 2014 "I want to help ... back but haven’t the money for chiropractors," said an ... have such a product for myself." , The Stretch ... stretch the thigh muscles and align the spine properly. ... relieves discomfort of pinched nerves. Compact and easy to ...
(Date:9/21/2014)... September 21, 2014 The Electronic ... and supports electronic medical records (EMR) and electronic ... federal healthcare legislation during the past five years ... during the five years to 2019. The 2009 ... Act established Medicare and Medicaid incentives to encourage ...
(Date:9/21/2014)... Best Cheap Hosting USA, one of the leading ... GreenGeeks are the best Reseller hosting suppliers in 2014. ... supplier. Actually, these companies have outperformed their competitors on ... can get the best web hosting at affordable rates,” ... the manager, reseller hosting is a very popular way ...
(Date:9/21/2014)... Originally approved by the Food ... (fluticasone propionate) is a synthetic ICS therapy with ... maintenance treatment of asthma prophylactically in children and ... Diskus and HFA, which received the FDA approval ... fluticasone propionate, can bind to glucocorticoid receptors with ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
Breaking Medicine News(10 mins):Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2
... University of New York at the Buffalo School of Dental ... fibrinogen, a protein useful in blood clotting may increase the ... gums, those with gum disease carry certain gene variations linked ... , 79 people with gum ...
... In a landmark breakthrough, scientists have created mice with unusually ... also opening a possibility of helping people forget their distressing ... the molecular processes that govern memory and learning in the ... Technology in Zurich. , ...
... expands into Optical Coherence Tomography. This breakthrough has made many ... This has been developed by Dr. Brett Bouma an assistant ... tomography to gauge stent status.// , ... ultrasound and will allow cardiologists to view the status of ...
... on more than 1600 women reveals that parathyroid hormone (parathormone) increases ... them. The same hormone is also useful in regulating calcium levels ... new aspect of the hormone guarding against fractures has opened up ... brittle bone disease as it is also known as.// , ...
... May 24th issue of Nature reveals that the Obesity Hormone ... in more complex way than previously believed. This break through ... Obesity and many nutrition related disorders like anorexia nervosa. Dr. ... led the study. , ...
... actually repair itself by growing new cells after a heart ... York and Italy. Dr. Piero Anversa and colleagues of the ... muscle cells called myocytes continued to divide after a heart ... team examined the hearts of 13 people who died within ...
Cached Medicine News:
This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
Conducting disposable filter-tips....
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
Medicine Products: